R Squared’s Teva Pharmaceuticals TEVA Stock Holding History

R Squared’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-900	Closed	-$19.8K	–	1388
2024 Q4	$19.8K	Buy	+900	New	+$16.4K	0.02%	882

Other funds holding TEVA

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

R Squared's TEVA Position: Q1 2025 in Review

R Squared sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 900 shares — an estimated $19.8K sold.

R Squared first reported a position in TEVA in Q4 2024 and held it in 1 quarter. The position peaked at $19.8K in Q4 2024. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

R Squared reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 900 Teva Pharmaceuticals shares in Q1 2025, an estimated $19.8K.
R Squared first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Teva Pharmaceuticals position peaked at $19.8K in Q4 2024.
560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.